RESEARCH TRIANGLE PARK, N.C., March 29, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc ., a clinical-stage oncology company, announced today that it will present preclinical data on trilaciclib, G1T38, and G1T48 at the 2017 American Association for Cancer Research (AACR) Annual Meeting, to be held April 1-5 in Washington, DC.
Details on the two poster presentations are as follows:
Title: Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models Abstract Number: 5628 Poster Session: Immune Checkpoints and Immunosurveillance, Section 25 Date: April 5, 2017 Time: 8 a.m. – 12 p.m. EDT Presenter: Jessica A. Sorrentino, Ph.D.; Senior Scientist, G1 Therapeutics, Inc.
Title: Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer Abstract Number: 5641 Poster Session: Clinical and Translational Endocrine Oncology, Section 27 Date: April 5, 2017 Time: 8 a.m. – 12 p.m. EDT Presenter: Suzanne E. Wardell, Ph.D.; Assistant Professor, Duke University School of Medicine
Abstracts for each poster and additional information on the meeting can be found on the AACR website: www.aacr.org/ .
About Trilaciclib (G1T28)
Trilaciclib is a potential first-in-class short-acting CDK4/6 inhibitor in development to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. Trilaciclib is administered intravenously prior to chemotherapy and has the potential to significantly improve treatment outcomes.
Trilaciclib is being evaluated in three randomized, placebo-controlled Phase 2 clinical trials: a study in newly diagnosed, treatment-naive small-cell lung cancer (SCLC) patients ( NCT02499770 ), a study in previously treated SCLC patients ( NCT02514447 ), and a study in patients with triple-negative breast cancer ( NCT02978716 ). A randomized, placebo-controlled Phase 2 trial evaluating trilaciclib in combination with atezolizumab and chemotherapy in SCLC patients will begin in the second quarter of 2017 ( NCT03041311 ).
About G1T38
G1T38 is a potential best-in-class oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. G1T38 was well-tolerated with no grade 3/4 adverse events in a Phase 1 study of 75 healthy subjects. G1T38 is currently being evaluated in combination with Faslodex® in a Phase 1b/2a study in patients with estrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer ( NCT02983071 ).
About G1T48
G1T48 is a proprietary, orally available, selective estrogen receptor degrader (SERD). In preclinical studies, G1T48 has been shown to be more potent than Faslodex® and to have superior anti-tumor efficacy versus other SERDs in development. G1T48 is on track for an Investigational New Drug (IND) application and/or Clinical Trial Application (CTA) submission in the fourth quarter of 2017.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 mvelleca@g1therapeutics.com Investors: Robert Uhl Westwicke Partners 858-356-5932 robert.uhl@westwicke.com Media: Laura Bagby 6 Degrees Communications 312-448-8098 lbagby@6degreespr.com
